The FDA approved a first-of-its-kind drug to prevent respiratory syncytial virus (RSV). RSV hospitalizes 58,000-70,000 babies and toddlers ever year, yet parents have had no preventative medication options. The medicine, called Beyfortus, is an antibody designed to train the child’s immune system how to fight off the virus. The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV. The first ever long-acting RSV drug, the drug is given as a one-time injection. The drug is 75% effective at stopping severe RSV cases in infants and toddlers after one RSV season, and eligible children can receive one dose per year.
Full Story: Associated Press